Loading patent…
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsShun-ichi Hata, Koji Mizuno, Yasuho Nishii, Etsuko Mitsuishi, Motoharu Shiba
Estimating the term…
A pharmaceutical composition for reducing the alcohol content or slowing the rate of increase thereof in the blood and inhibiting the accumulation of neutral lipid in the liver containing a uridine diphosphate as an effective ingredient and a method of the use thereof are disclosed.
A method for reducing the alcohol content or slowing the rate of increase thereof in the blood and inhibiting the accumulation of neutral lipid in the liver of human beings, which comprises administering to human beings, orally or parenterally, a pharmaceutical composition comprising an effective amount of a uridine diphosphate as an effective ingredient and a pharmaceutically acceptable carrier.
A method for slowing the rate of alcohol level increase in the blood and inhibiting the accumulation of neutral lipids in the liver, which comprises orally administering a pharmaceutical composition comprising an effective amount of uridine diphosphate as an active ingredient and a pharmaceutically acceptable carrier just before or at the time of intake of alcoholic drinks.
A method for slowing the rate of alcohol level increase in the blood and inhibiting the accumulation of neutral lipids in the liver, which comprises intravenously or intramuscularly injecting a pharmaceutical composition in the form of parenteral injection comprising an effective amount of a uridine diphosphate as an active ingredient and a pharmaceutically acceptable carrier just before or at the time of intake of alcoholic drinks.
A method for reducing the alcohol content of the blood and the accumulation of neutral lipid in the liver, which comprises orally administering to a patient suffering from alcoholism a pharmaceutical composition comprising an effective amount of a uridine diphospate as an active ingredient and a pharmaceutically acceptable carrier.
A method for reducing the alcohol content of the blood and the accumulation of neutral lipid in the liver, which comprises intravenously or intramuscularly administering to a patient suffering from alcoholism a pharmaceutical composition for the prevention and treatment of alcoholism in the form of parenteral injection comprising an effective amount of a uridine diphosphate as an active ingredient and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.
No related US applications are recorded in the indexed filing history.
Medicinal preparations containing organic active ingredients: carbohydrates; Sugars; Derivatives thereof
To sulfur, selenium or tellurium: to sulfur
Medicines and medical preparations
Sugars
Term ended 15 Nov 1994 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to a pharmaceutical composition and a method of use thereof; particularly it relates to a pharmaceutical composition containing a uridine diphosphate as an effective ingredient for prevention and treatment of alcoholism and a method of use thereof.
Ethanol has been generally taken as an alcoholic drink, but it often causes acute and chronic alcoholism. The intake of a large amount of alcoholic drinks in a short period of time depresses the central nervous system and, thus, causes acute alcoholism such as drunkenness, dead drunkenness and coma. When taking a large amount of alcoholic liquor regularly becomes a habit, certain serious physical and mental disorders known as chronic alcoholism result. In these cases, it has been observed that the amount of neutral lipid accumulated in the liver is unusually high and this becomes a cause of liver disorder.
An object of this invention is to provide a pharmaceutical composition for prevention and treatment of alcoholism, and another object of this invention is to provide a method of treating alcoholism by the use of the pharmaceutical composition for prevention and treatment of alcoholism.
This invention is further illustrated by the following Examples, but they are not to be construed as limiting the scope of this invention.
The Sprague Dawley strain male rats weighing 180.+-.30 g which had been fed rat food commercially available as CLEA CE-2 and prevented from eating food for 16 hours just before the experiment was started were divided into groups of 10 rats each. Each rat was orally administered with disodium uridine-5'-diphosphate (UDP-2Na) as a suspension in corn oil in a dose of 100 mg/kg body weight. Thirty minutes after the administration, each rat was orally administered with ethanol as a 50% aqueous solution in a dose of 6 g/kg. body weight and, 24 hours after the administration, the liver was taken out and an amount of neutral lipid contained therein was determined by the Van Handel and Zilver-Smit method. For control, a glucose aqueous solution having a caloric content equivalent to the same amount of ethanol was used instead of ethanol.
The results are shown in Table 1.